About satralizumab
Interleukin-6 receptor antagonist
Used for
- Treats neuromyelitis optica spectrum disorder in adults and children aged 12 years or older.
Usual adult dose
120 mg under the skin at weeks 0, 2, and 4, then every 4 weeks.
Usual dose in children
For ages 12 and older: 120 mg under the skin at weeks 0, 2, and 4, then every 4 weeks.
Common side effects
- Headache
- Joint pain
- Injection-site reactions
- Low white blood cell counts
Important warnings
- Infections can occur; avoid starting treatment during an active infection.
- Screen for hepatitis B and tuberculosis before treatment.
- Monitor liver enzymes and blood counts during treatment.
- Live vaccines are not recommended during treatment.
Pregnancy
Human pregnancy data are limited; potential fetal risk is uncertain.
Breastfeeding
It is unknown whether satralizumab passes into breast milk; effects on infants are uncertain.
Interactions
- May reduce the effects of some medicines processed by liver enzymes, including warfarin and certain statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.